www.genesisunicorn.com Open in urlscan Pro
202.181.170.92  Public Scan

Form analysis
0 forms found in the DOM

Text Content

HOME ABOUT US PRESS RELEASES OUR TEAM SEC FILINGS





Led by an experienced team that brings together complementary and best in class
financial, operational, capital markets, investment and sector expertise,
Genesis Acquisition Corp. is the ideal partner for bringing innovative ventures
to the public markets.






ABOUT US


Genesis Unicorn Acquisition Corp. is a is a blank check company formed for the
purpose of effecting a merger, capital stock exchange, asset acquisition, stock
purchase, reorganization or similar business combination with one or more
businesses.


PRESS RELEASES


Here you can access, consult and download our latest press releases, press kits
and news feed.


03-06-2023
03-06-2023
11-30-2022
05-04-2022
02-18-2022
02-15-2022


OUR MANAGEMENT TEAM


Adeoye OLUKOTUN MD & MPHChief Executive Officer

Dr. Adeoye (Oye) Olukotun, our Chief Executive Officer, has over 35 years in the
pharmaceutical industry. He is a Mayo Clinic trained cardiologist who currently
serves as the Chief Executive Officer of CR Strategies, LLC. He has served as
the Chief Executive Officer and President of Epigen Pharmaceuticals, Inc. from
June 2014 to the present time, and Vice Chairman of CardioVax, Inc., from
January 2013 to the present time. Dr. Olukotun served as the Chief Medical
Officer of VIA Pharmaceuticals Inc. from 2004 to 2008. He spent the first 20
years of his career in roles of increasing responsibility in clinical
development at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35
years of experience in the pharmaceutical industry and has been instrumental in
the approval and success of numerous cardiology and metabolic medicines,
including the first daily beta blocker and the first approved ACE inhibitor,
among others. Dr. Olukotun currently serves on the board of directors for Tonix
Pharmaceuticals Holding Corp., (NASDAQ: TNXP) and Arrowhead Pharmaceuticals,
Inc. (NASDAQ: ARWR). Dr. Olukotun received his Medical Doctor degree from the
Albert Einstein College of Medicine in New York in 1973, undertook his specialty
in cardiovascular medicine at the Mayo Clinic and Mayo Graduate School of
Medicine from 1973 to 1978 and received a master in public health degree from
Harvard University School of Public Health in 1983. Further, Dr. Olukotun
received his bachelor of arts from the University of North Carolina at Chapel
Hill in 1969.

Samuel LUI President, Chief Financial Officer & Director

Samuel Lui, our President, Chief Financial Officer and director, has over 23
years of experience in capital markets, investment banking, private equity,
accounting and auditing. Since July 2016, he has been the founder and managing
director of LV Capital Limited, a private investment company focused on later
stage/pre-IPO investments and specializes in helping investee companies to list
on major exchanges such as NASDAQ and The Stock Exchange of Hong Kong Limited
(“HKEX”). Since December 2011, he has served as a board member of the private
equity funds at Rockstead Capital Private Limited, a registered fund management
company under the Monetary Authority of Singapore. Since November 2016, he has
also been a non-executive director of EFT Solutions Holdings Limited
(HKEX:8062). From December 2013 to May 2015, Mr. Lui was the chief financial
officer of ELL Environmental Holdings Limited (HKEX: 1395). From May 2007 to May
2009, Mr. Lui was a director within the financial sponsors group, investment
banking division of Merrill Lynch in Hong Kong and Singapore. Prior to that, Mr.
Lui worked as an assistant director of the financial sponsors group at ABN AMRO
Bank N.V., Hong Kong branch, from August 2005 to April 2007. From July 2004 to
August 2005, Mr. Lui was a vice president at the project finance and advisory
department of Société Générale Asia Limited. Prior to that, Mr. Lui served as a
manager of project and export finance at The Hongkong and Shanghai Banking
Corporation Limited from May 2003 to June 2004. From August 1998 to April 2003,
Mr. Lui worked in the audit and corporate finance departments of Arthur Andersen
and Ernest & Young in Singapore. Mr. Lui obtained a bachelor’s degree in
accountancy from Nanyang Technological University in Singapore in July 1998. Mr.
Lui has been a member of the Institute of Singapore Chartered Accountants since
October 2002.

Niel STARKSEN MD Chief Scientific Officer

Dr. Niel Starksen, our Chief Scientific Officer, is an entrepreneur, physician
and scientist. He is a pioneer of percutaneous therapeutic technologies for
structural heart disease and congestive heart failure. Dr. Starksen is an
inventor on 18 issued patents and over 20 patents pending. Dr. Starksen
previously served as Chief Executive Officer of Guided Delivery Systems (now
known as Ancora Heart) from September 2002 to July 2015 and, since September
2018, is a director and cofounder of Vivalink Medical, a provider of connected
healthcare solutions for remote patient monitoring.He has been an advisor to
Xcures (a platform for virtual clinical trials) since September 2018, and an
advisor to Well Advised (a medical fintech platform) since September 2019. He is
a Director of the Board of Governors, Johns Hopkins Wilmer Eye Institute. Dr.
Starksen received his Medical Doctor degree from The John Hopkins University
School of Medicine in June 1982, completed an internal medicine residency
program at Harvard Medical School in April 1985 and completed his specialty in
cardiovascular medicine at the School of Medicine, University of California, San
Francisco in July 1990. Further, Dr. Starksen received his bachelor of science
degree with summa cum laude from University of California, Irvine in June 1978.

Juan FERNANDEZ Chief Operating Officer

Juan Fernandez Pascual, our Chief Operating Officer, served as the General
Manager of Chassis Brakes International Spain SLU, a division of Hitachi
Automotive Systems, based in San Felices de Buelna, Cantabria, Spain, from April
2019 to February 2021. Mr. Fernandez has served as a special advisor to
Benessere Capital Acquisition Corporation since November 2020. Benessere Capital
Acquisition is a similar special purpose acquisition company (SPAC) entity which
completed its initial public offering in January 2021. Benessere Capital
Acquisition has focused its search on technology-focused middle market and
emerging growth companies in North, Central and South America. Mr. Fernandez
served as the President of Gira Cluster of Automotive Industries of Cantabria
from May 2019 to March 2021 and was based in Spain. From September 2018 to April
2019, Mr. Fernandez served as the Smart Factory Platform Leader of Linxens based
in Levallois, Île-de-France, France. From January 2017 to April 2019, Mr.
Fernandez served as the Site Director of Linxens. From September 2015 to
December 2016, Mr. Fernandez served as the Senior Area Sales Manager Southern
Europe for Quintus Technologies, based in Vasteras, Sweden. From September 2014
to September 2015, Mr. Fernandez served as the Site Director of Hutchinson based
in Châteaudun, France. From April 2013 to August 2014, Mr. Fernandez served as
the Production Area Manager of Gestamp based in Le Theil, Basse-Normandie,
France. From November 2005 to March 2013, Mr. Fernandez served as Process
Engineer Manager at ArcelorMittal Aviles, Spain. From September 2003 to October
2005, Mr. Fernandez served as Resident Engineer of ArcelorMittal based
Electrolux premises in Conegliano, Veneto, Italy. In 2018, Mr. Fernandez
received his Executive MBA degree at ESCP Europe. In 1999, Mr. Fernandez
received his DEA (Master in Sciences) at Ecole Polytechnique.

Grainne COEN Co- Chairman

Grainne Coen, our Co-Chairman, is a board member of Commonwealth Credit Partners
BDC I, Inc., a business development company, and became Chair of the Audit
Committee since June 2021. In May 2018, she founded and has remained a partner
of Elevation Investment Partners, LLC, a diversified investment group operating
in multiple industries both as strategic consultants and early-stage investors.
Since January 2015, Ms. Coen has also served as Co-Founder and Chairperson of
AREA4, LLC, an experiential marketing agency. From August 2001 to December 2015,
she was a principal and portfolio manager at Columbia Partners, LLC Investment
Management, where she co-managed over $1 billion in assets held in the fund’s
U.S. Small Cap Equity Fund. From September 1998 to March 2001, she was a General
Partner at Kensington Partners, LLC, and from May 1996 to August 1998, she was
employed at G&O Partners, LP. Since October 2019, Ms. Coen also has served as
the Chair of the audit committee of Kubient, Inc. (NASDAQ: KBNT), a digital
marketing platform, and from March 2019 to December 2020, as Chair of the board
of directors of ERIE ARMADA, Inc., a non-profit focused on the development of
underserved communities in conjunction with New York City’s Parks and Trails
Department. Ms. Coen holds a Bachelor of Science from London Guildhall
University.

Ernest FONG Co-Chairman

Ernest Fong, our Co-Chairman, has, since October 2021, been the Asia Pacific CEO
of Optimas Capital, an Asian-based Hedge Fund with offices in Hong Kong,
Singapore and Taiwan. Mr. Fong joined Credit Suisse in March 1998 and after
spending more than 21 years in its Singapore, Taiwan and Hong Kong offices, he
retired from Credit Suisse in December 2019. His last position in Credit Suisse
was as the Head of Markets Research in Asia Pacific and he was responsible for a
team of almost 300 across 14 offices and 12 markets. Prior to Credit Suisse, Mr.
Fong was an equity research analyst at Credit Lyonnais Securities Asia from June
1995 to February 1998. Since June 2020, Mr. Fong is also a non-executive
director of Vincom Retail, listed in Vietnam, which is part of the Vincom group,
the largest privately-owned company in Vietnam. Ernest graduated from National
University of Singapore with a Bachelor of Arts degree, majoring in Economics
and Statistics.

Chung Fan CHENG Director

Chung Fan Cheng, our independent director, has over 17 years of experience in
capital markets, corporate strategy, private equity, family office and
entrepreneurship. Since Feb 2019, Mr. Cheng has served as the Chief Investment
Officer of BlueTop Group, a Hong Kong based family office with core focus in
education, human capital and technology. Mr. Cheng also serves as a
non-executive director of Tsui Wah Restaurant Group (HKEX:1314) since November
2016, and a director of Esperanza Limited, founded by the former financial
secretary of Hong Kong, since July 2021. Mr. Cheng’s prior work includes
management roles with Sail Global Capital from September 2017 to December 2018,
Hao Tian International Securities from September 2016 to August 2017, and KGI
Asia from April 2013 to September 2016. Mr. Cheng is an Engineer by training and
holds a M.Sc. Engineering Enterprise Management, HKUST, Hong Kong and B.Sc.
Engineering (1st Honors), Queen’s University, Canada.

Teck-Yong HENG Director

Teck-Yong Heng, one of our candidate for independent director will bring in more
than 20 years of private equity and M&A experience to the Company. Mr. Heng is a
partner and senior management in 58.com’s Investment Fund focusing on venture
capital and private equity investments in the TMT and Consumer sectors since
August 2021. Prior to joining in 58.com, Mr. Heng has operated C-Squared
Partners, a China focused consumer sector private equity fund since May 2018.
From August 2016 to May 2018, Mr. Heng was a managing director in Qianhai Ark
Asset Management, a fund with approximately $4.5 billion under management. Prior
to Qianhai Ark, Mr. Heng worked at Pavilion Capital (an affiliated entity of
Temasek Holdings) from September 2012 to July 2016, Temasek Holdings from
October 2004 to September 2012, Cambridge Associates from July 2003 to October
2004, Singapore Power International from June 2001 to July 2003, and Arthur
Andersen from July 1998 to May 2001. Mr. Heng has also served as independent
director for LiXiang Education Holding Co. Ltd. (NASDAQ: LXEH) since October
2020, and an independent director for WiMi Hologram Cloud Inc. (NASDAQ: WIMI)
since May 2021. Mr. Heng graduated from Nanyang Technological University with a
bachelor’s degree in Accountancy (with Honors) and is a graduate of Harvard
Business School’s General Management Program. He is a Chartered Financial
Analyst (CFA), Chartered Accountant (CA), Chartered International M&A Charter
holder, and a member of Singapore Institute of Directors.

Hank WUH MD & MPH Strategic and Scientific Advisor

Dr. Hank Wuh, our Strategic and Scientific Advisor, is a physician, inventor,
and entrepreneur. Dr. Wuh is Chief Scientific Officer of Pono Capital Corp.,
President of Unicorn Whisperer, Inc. since July 2018, a director of The Daily
Wellness Company since June 1996, and a director of Lymphax, Inc. since December
2019. Dr. Wuh is a Trustee of the University of Hawaii Foundation since April
2020, and an advisor to several medical technology companies. Dr. Wuh was the
CEO of SKAI Ventures from September 2010 to December 2019 and the Executive
Chairman of TruTag Technologies, Inc. from April 2011 to Aug 2018. Dr. Wuh was a
member of the Board of Directors of the Fulbright Association from January 2020
to August 2021, and a member of the Board of Directors of Cellular
Bioengineering, Inc. from August 2003 to August 2021. Dr. Wuh received his B.A.
from Johns Hopkins, a Master of Public Health from Harvard University School of
Public Health, Medical Doctorate from the Johns Hopkins University School of
Medicine, orthopedic surgery residency at Stanford, and is Associate Clinical
Professor of Surgery at the John A. Burns School of Medicine at the University
of Hawaii.

Robert CHANG MD Scientific Advisor

Dr. Robert Chang, our Scientific Advisor, is an associate professor and medical
innovator at Stanford University. He divides his time among state-of-the art
clinical eye care, clinical validation of digital health tools, and teaching
ophthalmology and healthcare innovation globally. He focuses on minimally
invasive glaucoma surgery (MIGS) and presbyopia-correcting cataract surgery with
emphasis on precision medicine. He is co-inventor of the first universal
smartphone adapter and the FDA-cleared PAXOS scope for portable imaging of the
front and back of the eye. He is on the advisory board for several ophthalmic
companies and serves as the Vice President of the Asia Pacific
Tele-Ophthalmology Society (APTOS).


SEC FILINGS


All filings for Genesis Unicorn Aquisition Corporation are publicly available
via EDGAR, and can be accessed and dowloaded through the US Security and
Exchange Commissions website following the link below.



Visit EDGAR Online









info@genesisunicorn.com